(February 16, 2021, 2:12 PM EST) -- BROOKLYN, N.Y. — A biotechnology company and certain of its senior executives violated federal securities laws by misrepresenting the impact the novel coronavirus pandemic was having on the company’s submission schedule for a U.S. Biologics Licensing Application (BLA) with the U.S. Food and Drug Administration, which caused the company’s stock price to trade at an artificially high rate until the fraud was disclosed to the investing public, a shareholder argues in a Feb. 12 complaint filed in New York federal court....